Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

Sponsor
University of California, San Diego
Study ID
NCT07116681
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pulmonary Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Inhaled treprostinil — DRUG
    Inhaled treprostinil is an inhaled prostacyclin analog which triggers pulmonary arterial dilation. This is the only intervention in this trial.

Study Details

This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and improve performance on exercise testing.

Key Dates

First listed
Aug 11, 2025
Start date
Oct 1, 2025
Status verified
Aug 2025
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group
    Single arm, every participant will receive inhaled treprostinil

Primary Outcome Measure

Stroke volume augmentation before and after inhaled treprostinil [ Time Frame: 30 minutes after initial dose of inhaled treprostinil ]

Central Contacts

Related Studies